Cover Image
市場調查報告書

高度惡性神經膠質瘤的開發中產品分析

High-Grade Glioma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 271830
出版日期 內容資訊 英文 162 Pages
訂單完成後即時交付
價格
Back to Top
高度惡性神經膠質瘤的開發中產品分析 High-Grade Glioma - Pipeline Review, H2 2016
出版日期: 2016年12月30日 內容資訊: 英文 162 Pages
簡介

高度惡性神經膠質瘤(HGG)是中樞神經系統(CNS)的腫瘤,發病於腦·脊椎的惡性轉換細胞。主要的症狀為發育遲緩和頭痛·背痛、噁心·嘔吐、暈眩、步行障礙、視力降低、集中力降低、睡意、睡眠障礙、不規則的食慾、麻痺·癲癇等。主要的治療方法有化療和放射治療等。

本報告提供全球各國治療量等級神經膠質瘤(Glioma)用的開發中產品開發情形相關分析,彙整產品開發·上市的最新趨勢,及臨床實驗各階段的產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

目錄

簡介

  • 分析範圍

高度惡性神經膠質瘤(Glioma)概要

治療藥的開發

  • 高度惡性神經膠質瘤開發中產品:概要
  • 高度惡性神經膠質瘤開發中產品:比較分析

各企業開發中的高度惡性神經膠質瘤治療藥

大學/研究機關研究中的高度惡性神經膠質瘤治療藥

開發中產品的概要

  • 臨床實驗階段的產品
  • 初期階段的產品

高度惡性神經膠質瘤治療藥:開發中的產品一覽(各企業)

高度惡性神經膠質瘤治療藥:研究中的產品一覽(大學/研究機關別)

高度惡性神經膠質瘤治療藥的開發企業

  • Boehringer Ingelheim GmbH
  • GlaxoSmithKline plc
  • Genentech, Inc.
  • Bayer AG
  • Virttu Biologics Limited
  • AngioChem Inc.
  • Stemline Therapeutics, Inc.
  • TAU Therapeutics, LLC
  • Tocagen Inc.
  • AROG Pharmaceuticals LLC

高度惡性神經膠質瘤:治療藥的評估

  • 單劑治療藥的情況
  • 並用治療藥的情況
  • 標的
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • nintedanib
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • ANG-1005
  • ANG-1005
  • (dabrafenib + trametinib)
  • Gene Therapy for High-Grade Glioma and Liver Transplantation
  • Dendritic Cell Vaccine
  • sorafenib tosylate
  • vocimagene amiretrorepvec + flucytosine ER
  • SL-701
  • crenolanib besylate
  • mibefradil dihydrochloride
  • GDC-0084
  • HSV-1716
  • TBX-01
  • Toca- RNAi

高度惡性神經膠質瘤治療藥:開發中產品的最新趨勢

高度惡性神經膠質瘤治療藥:暫停開發的產品

高度惡性神經膠質瘤相關產品的開發里程碑

  • 值得注意的最新趨勢·新聞稿(全2件)

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8917IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide High-Grade Glioma - Pipeline Review, H2 2016, provides an overview of the High-Grade Glioma (Oncology) pipeline landscape.

High­ly gra­de glio­mas (HGG) are tumors of the cen­tral ner­vous sys­tem (CNS) that ari­sing from trans­for­med cells of the brain and spi­nal cord. Symptoms include de­ve­lop­men­tal de­lay, head­a­ches, back­a­ches, nau­sea and vo­miting, diz­zi­ness, gait dis­tur­ban­ces, im­pai­red vi­si­on, lack of con­cen­tra­ti­on, drow­si­ness, sleep dis­tur­ban­ces, Dysregulated ap­pe­ti­te, pa­ra­ly­ses and sei­zu­res. Treatment includes Chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide High-Grade Glioma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for High-Grade Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The High-Grade Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for High-Grade Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 10, 10, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

High-Grade Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of High-Grade Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for High-Grade Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in High-Grade Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates High-Grade Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for High-Grade Glioma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for High-Grade Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding High-Grade Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • High-Grade Glioma Overview
  • Therapeutics Development
    • Pipeline Products for High-Grade Glioma - Overview
    • Pipeline Products for High-Grade Glioma - Comparative Analysis
  • High-Grade Glioma - Therapeutics under Development by Companies
  • High-Grade Glioma - Therapeutics under Investigation by Universities/Institutes
  • High-Grade Glioma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • High-Grade Glioma - Products under Development by Companies
  • High-Grade Glioma - Products under Investigation by Universities/Institutes
  • High-Grade Glioma - Companies Involved in Therapeutics Development
    • Advenchen Laboratories LLC
    • AngioChem Inc
    • Arog Pharmaceuticals Inc
    • Astellas Pharma Inc
    • Athenex Inc
    • Bayer AG
    • BTG Plc
    • Cavion LLC
    • CBT Pharmaceuticals Inc
    • DelMar Pharmaceuticals Inc
    • Merrimack Pharmaceuticals Inc
    • Millennium Pharmaceuticals Inc
    • Nektar Therapeutics
    • Novartis AG
    • Sanofi
    • Sumitomo Dainippon Pharma Co Ltd
    • Targepeutics Inc
    • Tocagen Inc
    • Virttu Biologics Ltd
    • ZIOPHARM Oncology Inc
  • High-Grade Glioma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AdRTSIL-12 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • alisertib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • bendamustine hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BMX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cabazitaxel - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBT-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Gliomas - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for High-Grade Glioma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crenolanib besylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dabrafenib mesylate + trametinib dimethyl sulfoxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dianhydrogalactitol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DSP-7888 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etirinotecan pegol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine + TBio-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GB-13 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HSV-1716 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride + TBio-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • irinotecan hydrochloride CR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KX-02 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mibefradil dihydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Oncolytic Virus for High-Grade Glioma and Melanoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • paclitaxel trevatide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RRX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sorafenib tosylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • High-Grade Glioma - Dormant Projects
  • High-Grade Glioma - Discontinued Products
  • High-Grade Glioma - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2015: Merrimack Pharmaceuticals Announces Data from an Investigator-Sponsored Phase 1 Study Showing Acceptable Safety Profile for MM-398 in High-Grade Glioma
      • May 28, 2015: Cavion to Present Clinical Trial Data at ASCO
      • May 31, 2014: Positive Data from Phase 2 Trial of NKTR-102 in Patients with Avastin®-Refractory High-Grade Glioma Presented at 50th ASCO Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for High-Grade Glioma, H2 2016
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • High-Grade Glioma - Pipeline by Advenchen Laboratories LLC, H2 2016
  • High-Grade Glioma - Pipeline by AngioChem Inc, H2 2016
  • High-Grade Glioma - Pipeline by Arog Pharmaceuticals Inc, H2 2016
  • High-Grade Glioma - Pipeline by Astellas Pharma Inc, H2 2016
  • High-Grade Glioma - Pipeline by Athenex Inc, H2 2016
  • High-Grade Glioma - Pipeline by Bayer AG, H2 2016
  • High-Grade Glioma - Pipeline by BTG Plc, H2 2016
  • High-Grade Glioma - Pipeline by Cavion LLC, H2 2016
  • High-Grade Glioma - Pipeline by CBT Pharmaceuticals Inc, H2 2016
  • High-Grade Glioma - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
  • High-Grade Glioma - Pipeline by Merrimack Pharmaceuticals Inc, H2 2016
  • High-Grade Glioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • High-Grade Glioma - Pipeline by Nektar Therapeutics, H2 2016
  • High-Grade Glioma - Pipeline by Novartis AG, H2 2016
  • High-Grade Glioma - Pipeline by Sanofi, H2 2016
  • High-Grade Glioma - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2016
  • High-Grade Glioma - Pipeline by Targepeutics Inc, H2 2016
  • High-Grade Glioma - Pipeline by Tocagen Inc, H2 2016
  • High-Grade Glioma - Pipeline by Virttu Biologics Ltd, H2 2016
  • High-Grade Glioma - Pipeline by ZIOPHARM Oncology Inc, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • High-Grade Glioma - Dormant Projects, H2 2016
  • High-Grade Glioma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for High-Grade Glioma, H2 2016
  • Number of Products under Development for High-Grade Glioma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top